Biosafety risk assessment of a clinical biochemistry laboratoryfor SARS-CoV2 infection

Basit Öğe Kaydı
dc.contributor.authorZorbozan, Orçun
dc.contributor.authorZorbozan, Nergiz
dc.date.accessioned2023-01-12T20:27:16Z
dc.date.available2023-01-12T20:27:16Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractObjectives: Clinical laboratories are a transfer point for infected patient samples. According to the World Health Or ganization (WHO) Laboratory Biosafety Guideline, a risk assessment approach is the backbone of laboratory biosafety.In laboratories, risk assessment is recommended at predetermined periods and in the event of new circumstances.On February 12, 2020, the WHO published an interim guidance document, "Laboratory biosafety guidance relatedto the novel coronavirus (2019-nCoV)" and it was highly recommended that all coronavirus 2019 (COVID-19) testingprocedures be performed based on a local risk assessment. This study was designed to evaluate the biosafety risk in abiochemistry laboratory where routine testing of patients diagnosed with COVID-19 is performed. Methods: Risk assessment for tests performed on analyzers and a complete urinalysis was performed using the riskassessment template included in the subsequent WHO interim guidance document, “Laboratory biosafety guidancerelated to coronavirus disease (COVID-19).” Results: The overall initial risk for tests performed on analyzers and a complete urinalysis test was determined to bevery high. Processes such as pipetting a sample and checking a sample tube by scanning the barcode during testsperformed on analyzers were suspended until additional risk control measures could be implemented. The manualmicroscopic urinalysis process was also discontinued. To reduce the risk, surgical masks, surgical caps, eye protection,and disposable laboratory coats were added to the previously mandated personal protective equipment. After imple menting additional risk control measures, the total residual risk of both processes was graded medium. Conclusion: Since there is as yet no effective treatment for COVID-19, exposure risk is considered severe. Therefore, theprobability of exposure is important in determining the level of risk. Measures put in place reduced the total residual risk.en_US
dc.identifier.doi10.14744/ijmb.2021.28290
dc.identifier.endpage120en_US
dc.identifier.issn2587-2362
dc.identifier.issn2618-642X
dc.identifier.issue2en_US
dc.identifier.startpage104en_US
dc.identifier.trdizinid487392en_US
dc.identifier.urihttps://doi.org/10.14744/ijmb.2021.28290
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/487392
dc.identifier.urihttps://hdl.handle.net/11454/80228
dc.identifier.volume4en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofInternational Journal of Medical Biochemistryen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleBiosafety risk assessment of a clinical biochemistry laboratoryfor SARS-CoV2 infectionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu